Trade

with

Provectus Biopharmaceuticals Inc
(Amex: PVCT)
AdChoices
0.9800
-0.0088
-0.89%
After Hours :
-
-
-

Open

0.9700

Previous Close

0.9888

Volume (Avg)

553.67k (635.20k)

Day's Range

0.9600-1.03

52Wk Range

0.3000-3.75

Market Cap.

173.11M

Dividend Rate ( Yield )

-

Beta

1.06

Shares Outstanding

176.64M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 0

    • Net Income

    • -27.70M

    • Market Cap.

    • 173.11M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.06

    • Forward P/E

    • -

    • Price/Sales

    • -

    • Price/Book Value

    • 8.67

    • Price/Cash flow

    • -13.77

      • EBITDA

      • -12.35M

      • Return on Capital %

      • -181.11

      • Return on Equity %

      • -216.55

      • Return on Assets %

      • -181.11

      • Book Value/Share

      • 0.11

      • Shares Outstanding

      • 176.64M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 3.50

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.15

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 22.20

              • 1.52

              • Quick Ratio

              • 22.20

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.11

              • 1.91

              • Book Value/Share

              • 0.11

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.42

                • 63.69

                • P/E Ratio 5-Year High

                • -33.04

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.64

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.64

                • Price/Book Value

                • 8.74

                • 3.39

                • Price/Cash Flow Ratio

                • -13.77

                • 21.79

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -216.55

                    (-285.50)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -181.11

                    (-169.30)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -216.55

                    (-285.50)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • -

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -13.03M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -13.77
                  Ownership

                  Institutional Ownership

                  2.40%

                  Top 10 Institutions

                  2.29%

                  Mutual Fund Ownership

                  1.68%

                  Float

                  93.55%

                  5% / Insider Ownership

                  8.83%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Commonwealth Equity Services Inc

                  •  

                    81,500

                  • 0.00%

                  • 0.05

                  • Creative Planning, Inc.

                  •  

                    48,900

                  • +55.73%

                  • 0.03

                  • Hudson Canyon Investment Counselors L.L.

                  •  

                    25,000

                  • 0.00%

                  • 0.01

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Core

                  Provectus Biopharmaceuticals Inc is a Delaware corporation formed in 2002. The Company along with its subsidiaries is a development-stage biopharmaceutical company that is engaged in developing pharmaceuticals for oncology and dermat...moreology indications. The Company is engaged in developing its prescription drug candidates PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. It is also developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. It holds a number of U.S. patents covering the technologies it has developed and is continuing to develop for the production of prescription drugs, non-core technologies an...mored OTC pharmaceuticals. The Company complies with all the regulations prescribed by FDA prior to sales within the United States and by comparable foreign agencies prior to sales outside the United States.lessless

                  Key People

                  H. Craig Dees,PhD

                  CEO/Chairman of the Board/Director

                  Peter R. Culpepper

                  CFO/COO/Secretary

                  Timothy C. Scott,PhD

                  Director/President

                  Dr. Kelly M. McMasters,M.D.,PhD

                  Director

                  Mr. Alfred E. Smith, IV

                  Director

                  • Provectus Biopharmaceuticals Inc

                  • 7327 Oak Ridge Highway

                  • Knoxville, TN 37931

                  • USA.Map

                  • Phone: +1 866 594-5999

                  • Fax: +1 866 998-0005

                  • pvct.com

                  Incorporated

                  2002

                  Employees

                  4

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: